Cerenome Publishes Presentation on 186RNL Survival Benefits in Preclinical Ovarian Cancer Models

• Cerenome published a medical research poster on rhenium-186 nanoliposome (186RNL) in preclinical ovarian cancer models.
• Combining 186RNL with anti-PD-1 increased median survival to 65 days in the ID8agg mouse model, without substantial added toxicity.
• Combination therapy reduced tumor burden versus control and either monotherapy, shifting the tumor immune microenvironment toward an effector-dominant response.
• In the KPCA model, 186RNL significantly reduced tumor burden but showed no significant overall survival benefit (p = 0.668; eight mice per group).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.